Hosted on MSN9mon
Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer
The treatment guidelines for non-muscle-invasive bladder cancer (NMIBC) consist of endoscopic resection of the tumor, then administration of drugs into the bladder (intravesical therapy ...
Business Wire6d
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that ...
Nature15y
Intravesical MCC for bladder cancer
Mycobacterial cell wall–DNA complex (MCC) is an effective treatment modality for bladder cancer, and has a favorable safety profile when compared with intravesical therapy using live bacillus ...
Nature5y
Adjuvant, intravesical BCG therapy is cost-effective
Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...
UroToday5d
SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Abstract/Posters Session. Dr Madison Wahlen discussed ...